ArticleFrontiers in pharmacology2023

A glycoengineered therapeutic anti-HBV antibody that allows increased HBsAg immunoclearance improves HBV suppression

Min You et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.